FAlternatives to Farxiga — Science-led biopharmaceutical medicine for cardiovascular, renal and metabolic conditions.
People searching for Farxiga alternatives are usually managing type 2 diabetes, heart failure with reduced ejection fraction or chronic kidney disease and want to compare SGLT2 inhibitors or other cardiorenal therapies. Farxiga (dapagliflozin) is an AstraZeneca therapy within the Cardiovascular, Renal and Metabolism portfolio that lowers glucose, reduces heart-failure hospitalizations and protects kidney function. Users often look for options with different dosing, side-effect profiles, cost, or additional benefits such as greater weight loss or once-weekly administration. Common considerations include insurance coverage, generic availability, and suitability for patients with specific comorbidities. This page reviews well-known prescription alternatives so patients and clinicians can make informed comparisons based on clinical data and real-world use.
Enhertu is AstraZeneca and Daiichi Sankyo's approved HER2-directed ADC used across multiple solid tumours. It offers strong clinical efficacy and a cleavable linker but relies on single-antigen targeting without logic gating. Compared with Valink Therapeutics, Enhertu has far greater clinical validation and commercial scale while Valink's V-Gate bispecific design seeks improved selectivity and resistance overcoming in earlier discovery stages.
Equator TherapeuticsMounjaro (tirzepatide) is Eli Lilly’s dual GIP/GLP-1 agonist that delivers greater weight reduction than semaglutide in head-to-head data. It acts centrally on appetite pathways rather than mitochondrial heat production. Equator’s preclinical mechanism could complement or differ from incretin drugs by targeting energy expenditure directly, though Mounjaro is already marketed while Equator remains pre-clinical.
Gilead Sciences (Kite Pharma)Trodelvy is Gilead's TROP-2 directed ADC approved for breast and urothelial cancers. It uses a moderately toxic payload and standard targeting. Versus Valink, Trodelvy provides real-world use data and broader indications today, whereas Valink's dual-target V-Gate approach aims for tighter tumour restriction and new payload opportunities not yet clinically tested.
MounjaroMounjaro (tirzepatide) is Eli Lilly’s dual GIP/GLP-1 agonist that delivers greater weight reduction than semaglutide in head-to-head data. It acts centrally on appetite pathways rather than mitochondrial heat production. Equator’s preclinical mechanism could complement or differ from incretin drugs by targeting energy expenditure directly, though Mounjaro is already marketed while Equator remains pre-clinical.
AdcetrisAdcetris (brentuximab vedotin) from Seagen/Pfizer was one of the first approved ADCs targeting CD30 in lymphomas. It demonstrates durable responses but faces resistance issues common to single-target ADCs. Valink Therapeutics positions its bispecific V-Gate candidates as potential solutions for similar resistance mechanisms through multi-antigen logic in solid tumours where Adcetris is not indicated.
Roche VentanaPolivy is Roche's CD79b-targeted ADC approved for diffuse large B-cell lymphoma in combination regimens. It shows strong activity in hematologic malignancies. Valink focuses on solid tumour programs with continuous-level gating technology that Polivy lacks, targeting different biology and tissue distribution challenges.
OrlistatAlli/Xenical (orlistat) is an OTC or prescription lipase inhibitor that reduces dietary fat absorption. It offers modest weight loss with GI tolerability issues and no impact on mitochondrial function. Equator’s thermogenic strategy aims for active calorie burning rather than passive malabsorption, representing a mechanistically distinct alternative for patients seeking sustained results.
BlenrepGSK's Blenrep is a BCMA-directed ADC for multiple myeloma that was later withdrawn in some markets due to safety concerns. Its experience highlights the need for improved selectivity. Valink's V-Gate platform is designed to enhance tumour-versus-healthy discrimination, potentially mitigating similar toxicity risks in future ADCs.
QsymiaQsymia combines phentermine and topiramate for appetite suppression and satiety. It is an oral generic-option drug with cardiovascular monitoring requirements. Equator’s mitochondrial program targets energy expenditure biology instead of CNS appetite circuits, potentially avoiding stimulant-related side effects while addressing a different physiological lever.
ContraveContrave pairs naltrexone and bupropion to modulate reward pathways and reduce cravings. Like other approved oral agents, it does not stimulate thermogenesis. Equator’s first-in-class mitochondrial activator could appeal to patients who have not responded to or tolerated existing CNS-acting weight-loss medications.
Mersana TherapeuticsMersana develops next-generation ADCs with novel payloads and linkers, including Dolasynthen and Immunosynthen platforms. Their work emphasises tolerability and new targets. Compared with Valink, Mersana has more disclosed clinical assets while Valink's LiliumX AI engine and V-Gate logic provide a differentiated discovery approach for bispecific constructs.
ProscarMetformin is the widely used first-line type 2 diabetes drug that modestly affects weight via hepatic glucose production. It has some mitochondrial effects but is not developed as a thermogenic agent. Equator’s targeted uncoupler program aims for more potent, selective activation of heat production than metformin’s indirect actions.